# UnitedHealth Group (UNH) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/UNH
## Company Profile
- Ticker: UNH
- Exchange: NYSE
- Sector: Healthcare Services
- Location: United States
- Tags: Healthcare Services
## Stock Data
- Close: 405.59 USD
- Market cap: 343205933159.68 USD
- Last updated: 2026-08-12
## Business Overview
UnitedHealth Group is a diversified healthcare company with insurance, care delivery, and services operations through UnitedHealthcare and Optum. The company’s story is driven more by managed-care scale, services growth, and operating execution than by classic biotech catalysts.
## Why The Stock Is Moving

As of Aug 12, 2026, UNH closed up 0.85% at $405.59. No new same-company headline was identified in the current news window.

## Geographic Base

Headquartered in the United States and listed on NYSE, UnitedHealth sits in managed care and healthcare services. Its geographic footprint is broad and largely U.S.-centered, with a large national commercial presence.

## Business Model

The business combines premium revenue, healthcare services, data-enabled operations, and care delivery infrastructure. Investors tend to watch membership trends, medical cost ratios, Optum growth, and regulatory or reimbursement pressure.

## Landscape Position

UnitedHealth is not a biotech company, but it matters to healthcare investors because it sits at the center of payer and provider economics. Its stock is driven by operational and policy factors rather than drug-development catalysts.

## Future Catalysts

- UnitedHealth Group's catalyst setup now looks most tied to CRB-701, CANYON-1, and the rest of its current pipeline. What gives this more shape is “Having reached broad alignment with the FDA, we’re on track to start a registrational study for CRB-701 in second-line HNSCC this summer. That setup makes the next update more important than the headline financials themselves.

## Drug Assets

- CRB-701

## Recent News
- 2026-08-06 12:00 EST — [Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update](https://biopharmsignal.com/news/UNH/corbus-pharmaceuticals-reports-q2-2026-financial-results-and-provides-a-corporat-cb7ad5a0) — Source: UnitedHealth Group
- 2026-08-04 12:30 EST — [Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity](https://biopharmsignal.com/news/UNH/corbus-pharmaceuticals-announces-last-patient-last-visit-in-canyon-1-study-of-cr-9d359b65) — Source: UnitedHealth Group
- 2026-07-28 12:00 EST — [Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer](https://biopharmsignal.com/news/UNH/corbus-pharmaceuticals-announces-fda-clearance-to-initiate-tempo-1-registrationa-5499960d) — Source: UnitedHealth Group
- 2026-07-06 12:00 EST — [Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer](https://biopharmsignal.com/news/UNH/corbus-pharmaceuticals-appoints-leonardo-viana-nicacio-m-d-as-chief-medical-offi-7e9400c6) — Source: UnitedHealth Group
- 2026-05-26 11:00 EST — [Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers](https://biopharmsignal.com/news/UNH/corbus-pharmaceuticals-reports-updated-crb-701-phase-1-2-clinical-data-demonstrating-robust-activity-in-2l-oropharyngeal-and-cervical-cancers) — Source: UnitedHealth Group